Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques

Abstract

Saquinavir appears to be well-suited to first-line monotherapy or combination therapy without prejudicing subsequent or concurrent use of other proteinase inhibitors not affected by mutations at codons 48 and 90.